OncoMatch

OncoMatch/Clinical Trials/NCT04290663

Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up

Is NCT04290663 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Systematic RAI-treatment for thyroid cancer.

Phase 3RecruitingCentre Francois BaclesseNCT04290663Data as of Jun 2026Location: France

Treatment: Systematic RAI-treatmentThis trial is comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine administration versus decision of radioiodine treatment guided by a post-operative work-up based on serum Tg values and diagnostic RAI scintigraphy

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Systematic RAI-treatment

Cancer type

Tumor Agnostic

Disease stage

Excluded: Stage PT1A, PT3, PT4, PT1AN0/X, PT1BN0/X, PT2N0/NX, PT1AN1 WITHOUT EXTRA-THYROID EXTENSION AND WITH NODAL LARGEST DIMENSION <2MM, PT1BN1 WITHOUT EXTRA-THYROID EXTENSION AND WITH NODAL LARGEST DIMENSION <2MM, PT2N1 WITHOUT EXTRA-THYROID EXTENSION AND WITH NODAL LARGEST DIMENSION <2MM, PT1AN1 WITHOUT EXTRA-THYROID EXTENSION AND WITH NODAL LARGEST DIMENSION >10MM, PT1BN1 WITHOUT EXTRA-THYROID EXTENSION AND WITH NODAL LARGEST DIMENSION >10MM, PT2N1 WITHOUT EXTRA-THYROID EXTENSION AND WITH NODAL LARGEST DIMENSION >10MM, PT2N0/NX WITHOUT EXTRA-THYROID EXTENSION, PT3B

T1b or T2 with minimal extra-thyroid extension into the perithyroidal soft tissues and/or pN1 with largest nodal dimension between 2 and 10 mm, without extra-capsular invasion and with a number of metastatic nodes ≤ 10 T1aN1 with largest nodal dimension between 2 and 10 mm, without extra-capsular invasion and with a number of metastatic nodes ≤ 10

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: total thyroidectomy

Patient treated by total thyroidectomy with macroscopically complete tumor resection (R0 or R1) ± neck dissection

Must have received: LT4 treatment

Post-operative LT4 treatment initiated at least 6 weeks before randomization

Cannot have received: lobectomy only

Patients who have undergone lobectomy only

Cannot have received: previous RAI treatment for thyroid cancer

Previous RAI treatment for thyroid cancer

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT04290663 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior lobectomy only, previous RAI treatment for thyroid cancer disqualifies patients from enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify